Inhibiting PIM2 sensitizes CML to Gleevec
INDICATION: Chronic myelogenous leukemia (CML)
Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA were higher in CML stem cells, which are resistant to Gleevec, than in hematopoietic stem cells (HSCs). In patient-derived CML stem cells, two shRNAs targeting PIM2, a pan-PIM kinase inhibitor tool compound or the pan-PIM kinase inhibitor PIM447 increased sensitivity to Gleevec compared with a non-targeting shRNA or vehicle. In the CML stem cells, patient-derived HSCs and two Gleevec-resistant human CML cell lines, the pan-PIM kinase inhibitor tool compound plus Gleevec decreased proliferation compared with either agent alone. In a mouse model of CML, the combination increased survival and decreased leukemic burden in the peripheral blood. In a patient-derived xenograft (PDX) mouse model of CML, the combination decreased leukemic burden in the peripheral blood and spleen. Next steps could include testing selective PIM2 inhibitors in the models...
BCIQ Company Profiles